Compare IDCC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | CORT |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 3.7B |
| IPO Year | 2007 | 2001 |
| Metric | IDCC | CORT |
|---|---|---|
| Price | $373.78 | $35.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $412.50 | $105.20 |
| AVG Volume (30 Days) | 276.8K | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.80 | 0.82 |
| Revenue | $307,404,000.00 | ★ $761,407,000.00 |
| Revenue This Year | N/A | $30.63 |
| Revenue Next Year | $3.38 | $31.61 |
| P/E Ratio | ★ $31.53 | $43.02 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $180.60 | $28.66 |
| 52 Week High | $412.60 | $117.33 |
| Indicator | IDCC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 36.34 |
| Support Level | $353.39 | $33.53 |
| Resistance Level | $383.13 | $41.92 |
| Average True Range (ATR) | 16.91 | 2.56 |
| MACD | 0.77 | 0.35 |
| Stochastic Oscillator | 73.35 | 53.65 |
InterDigital Inc is a research and development company focused on wireless, video, Artificial Intelligence, and related technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, out of which the majority is from China.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.